Sofosbuvir Combo Shows Promise for effective treatment of HCV patients with CKD on hemodialysis

• The study, which included 54 hemodialysis patients with HCV, unveiled some compelling findings.
• Genotype 1 emerged as the most prevalent, affecting 75.9% (n = 41) of the participants.
• An impressive 96.29% (n = 52) of the patients achieved sustained virological response (SVR) at the study's conclusion, signalling a successful clearance of the virus from their bodies.
• Even more promising, none of the patients experienced severe side effects necessitating a reduction in treatment doses or discontinuation.

These results indicate that the combination therapy involving sofosbuvir demonstrates a high level of efficacy among dialysis patients, irrespective of their HCV genotype or the presence of cirrhosis. Moreover, this treatment approach requires minimal monitoring, mirroring the successful outcomes observed in non-chronic kidney disease (CKD) patients.

The findings offer hope for patients with HCV infection receiving hemodialysis in India, potentially paving the way for more accessible and effective treatment options in the future. With the threat of HCV significantly reduced, these patients may enjoy improved health and well-being, contributing to an overall better quality of life.

Reference:

Sahay M, Priyashree, Ismal K, et al. Efficacy and Safety of Directly Acting Antivirals in Patients with Hepatitis C Infection on Hemodialysis. J Assoc Physicians India 2023;71(8):25–28. https://www.japi.org/y2648454/efficacy-and-safety-of-directly-acting-antivirals-in-patients-with-hepatitis-c-infection-on-hemodialysis